However, a significant challenge in evaluating kidney outcomes lies in the inconsistent definitions of renal endpoints across studies, particularly regarding the thresholds for substantial eGFR decline, which vary from 30% to 57%
People should also talk to their health care provider before any planned surgeries or procedures and be prepared to discuss their up-to-date medical history, including a current list of prescribed medications and treatments
The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
Sabina Hemmi, the cofounder and chief executive of the GLP-1 provider comparison startup GLP Winner, says she no longer even attempts to track new startups, because there are simply too many
doi: 10.1161/CIR.0000000000001209